Dendritic Cell Therapy Shows Promise in Early HER2 Breast Cancer

Intratumoral dendritic cell therapy, when combined with HER2-targeted treatment, has demonstrated potential to enhance immune activity and improve pathologic complete response rates in patients with early-stage HER2-positive breast cancer. These findings were presented at the American Society of Clinical Oncology (ASCO) meeting this week.

The phase II study involved 40 participants diagnosed with HER2-positive breast cancer. The combination therapy aimed to stimulate the patient's own immune system to better target and eliminate cancer cells. Preliminary data indicated a higher rate of complete eradication of tumor cells in the breast and lymph nodes among patients receiving the experimental dendritic cell therapy alongside standard HER2-targeted agents, compared to historical controls.

Researchers highlighted that the dendritic cells, a type of immune cell, were administered directly into the tumor site. This localized delivery is believed to prime the immune system more effectively against the cancer. While the exact mechanisms are still under investigation, the therapy appears to augment the anti-tumor immune response, potentially making it more durable and effective.

Further analysis of the data is ongoing, with a focus on long-term outcomes, including recurrence-free survival and overall survival. The encouraging results from this phase II trial are expected to pave the way for larger, randomized phase III studies to definitively establish the efficacy and safety of this novel therapeutic approach. The ASCO presentation generated significant interest among oncologists specializing in breast cancer treatment.